Zanubrutinib is used to treat mantle cell lymphoma (MCL; a fast-growing cancer that begins in the cells of the immune system) in adults who have already been treated with at least one other chemotherapy medication. It is grouped under the following drug class(es): Antineoplastic agents, Kinase inhibitors and Tyrosine Kinase Inhibitors. Its therapeutic use is listed as anti-cancer agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include BDBM250082 and Brukinsa (TN). Its PubChem CID is 135565884.
Zanubrutinib
| CAS No | 1691249-45-2 |
|---|---|
| Molecular Formula | C27H29N5O3 |
| Molecular Weight | 471.50 g/mol |
| Synonyms | (7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Zanubrutinib is used to treat mantle cell lymphoma (MCL; a fast-growing cancer that begins in the cells of the immune system) in adults who have already been treated with at least one other chemotherapy medication.
The listed CAS number is 1691249-45-2.
The listed molecular formula is C27H29N5O3.
The listed molecular weight is 471.50 g/mol.
(7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide.
The source lists BDBM250082 and Brukinsa (TN).